Answers are grounded in this paper and cite their sources.
At the dosages and schedules used in the present study, doxorubicin achieves better disease and symptom control than paclitaxel in first-line treatment. Doxorubicin and paclitaxel are not totally cross-resistant, which supports further investigation of these drugs in combination or in sequence, both in advanced disease and in the adjuvant setting.
No takes yet. Share an insight, caveat, or question.
Paridaens et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: